Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Valproic acid
Drug ID BADD_D02329
Description Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton.[A178051] It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investigations into the anticonvulsant effects of khelline when he found that all of his samples, dissolved in valproic acid, exerted a similar degree of anticonvulsive activity. It first received approval on February 28, 1978 from the FDA under the trade name Depakene.[L6190] Since then, it has been investigated for neuroprotective, anti-manic, and anti-migraine effects. It is currently a compound of interest in the field of oncology for its anti-proliferative effects and is the subject of many clinical trials in a variety of cancer types.
Indications and Usage For treatment and management of seizure disorders, mania, and prophylactic treatment of migraine headache. In epileptics, valproic acid is used to control absence seizures, tonic-clonic seizures (grand mal), complex partial seizures, and the seizures associated with Lennox-Gastaut syndrome.
Marketing Status Prescription; Discontinued
ATC Code N03AG01
DrugBank ID DB00313
KEGG ID D00399
MeSH ID D014635
PubChem ID 3121
TTD Drug ID D03LGY
NDC Product Code 0591-4012; 17856-0152; 63629-2454; 72189-267; 60432-621; 0121-4675; 72189-010; 43353-085; 17349-0005; 68108-0203; 71930-057; 69452-150; 62756-920; 66064-8001; 17856-0675; 11014-0054; 0121-1350; 0615-8205; 68094-701; 43353-107; 10888-8132; 11014-0050; 70518-0079; 63739-253; 70518-0730; 42291-844; 0832-0310; 23639-0003; 50383-792; 68094-193; 0121-0675; 0527-5250; 49452-8092; 63739-086; 68925-0002; 43353-279; 63629-7597; 60687-262
Synonyms Valproic Acid | 2-Propylpentanoic Acid | 2 Propylpentanoic Acid | Divalproex | Depakene | Convulsofin | Depakote | Dipropyl Acetate | Divalproex Sodium | Semisodium Valproate | Vupral | Valproic Acid, Sodium Salt (2:1) | Propylisopropylacetic Acid | Ergenyl | Magnesium Valproate | Valproate | Valproate Sodium | Sodium Valproate | Calcium Valproate | Valproate Calcium | Depakine
Chemical Information
Molecular Formula C8H16O2
CAS Registry Number 99-66-1
SMILES CCCC(CCC)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionCytochrome P450 1A2P05177Not AvailableNot Available
HepatotoxicityCytochrome P450 2E1P05181Not AvailableNot Available
HepatotoxicityCytochrome P450 2C9P11712T19244Not Available
HepatotoxicityCytochrome P450 2A6P11509T06455Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Chronic myeloid leukaemia01.10.07.001; 16.01.07.0010.000231%Not Available
Circulatory collapse24.06.02.0010.000173%Not Available
Clavicle fracture15.08.03.010; 12.04.01.0100.000443%Not Available
Cleft lip15.11.05.002; 07.05.08.002; 03.11.05.0020.001329%Not Available
Cleft lip and palate07.05.08.003; 03.04.02.0030.000443%Not Available
Cleft palate03.04.02.001; 07.05.08.0010.003322%Not Available
Clonus17.02.05.0020.000443%Not Available
Coagulation factor decreased13.01.02.0160.000443%Not Available
Coagulopathy01.01.02.0010.002436%Not Available
Coarctation of the aorta24.04.01.002; 03.07.08.0010.000289%Not Available
Colitis07.08.01.0010.000886%
Coma17.02.09.0010.016830%Not Available
Completed suicide08.04.01.010; 19.12.01.0010.002888%Not Available
Concussion17.11.01.004; 12.01.10.0050.000443%Not Available
Conduction disorder02.03.01.0080.000116%
Confusional state19.13.01.001; 17.02.03.0050.008193%
Congenital anomaly03.02.01.001--Not Available
Congenital cystic kidney disease03.06.01.003; 20.01.04.006; 16.27.01.0020.000443%Not Available
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.001--
Coordination abnormal17.02.02.0040.002879%Not Available
Cough22.02.03.001--
Crying19.04.02.002; 17.02.05.013; 12.02.11.001; 08.01.03.0050.001107%Not Available
Cryptorchism05.05.02.002; 03.03.01.001; 21.15.01.0010.001993%Not Available
Cutaneous vasculitis24.05.02.004; 23.06.02.001; 10.02.02.003--Not Available
Cyanosis24.03.01.007; 22.02.02.007; 02.01.02.0020.001993%
Cyst16.02.02.002; 08.03.05.001--Not Available
Cystitis20.03.02.002; 11.01.14.001--
Dacryostenosis congenital06.06.04.008; 03.01.04.0010.000173%Not Available
Deafness04.02.01.0010.002436%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 30 Pages